ATE210721T1 - Verwendung eines mbp peptides zur herstellung eines medikamentes für die behandlung von multipler sclerose - Google Patents

Verwendung eines mbp peptides zur herstellung eines medikamentes für die behandlung von multipler sclerose

Info

Publication number: ATE210721T1
Authority: AT; Austria
Prior art keywords: multiple sclerosis; directed; medication; treatment; production
Prior art date: 1990-03-30

Application number

AT91910085T

Other languages

English (en)

Inventor

Kai W Wucherpfenning

Howard L Weiner

David Allen Hafler

Original Assignee

Brigham & Womens Hospital

Autoimmune Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1990-03-30

Filing date

1991-03-29

Publication date

2001-12-15

1991-03-29 Application filed by Brigham & Womens Hospital, Autoimmune Inc filed Critical Brigham & Womens Hospital

2001-12-15 Application granted granted Critical

2001-12-15 Publication of ATE210721T1 publication Critical patent/ATE210721T1/de

Links

201000006417 multiple sclerosis Diseases 0.000 title abstract 3
108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
239000003814 drug Substances 0.000 title abstract 2
229940079593 drug Drugs 0.000 title 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 3
102000004196 processed proteins & peptides Human genes 0.000 abstract 2
KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 abstract 1
238000009007 Diagnostic Kit Methods 0.000 abstract 1
101001018318 Homo sapiens Myelin basic protein Proteins 0.000 abstract 1
102000047918 Myelin Basic Human genes 0.000 abstract 1
101710107068 Myelin basic protein Proteins 0.000 abstract 1
230000002238 attenuated effect Effects 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
238000002405 diagnostic procedure Methods 0.000 abstract 1
102000054064 human MBP Human genes 0.000 abstract 1
230000028993 immune response Effects 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
229940124597 therapeutic agent Drugs 0.000 abstract 1
229960005486 vaccine Drugs 0.000 abstract 1
-1 vaccines Proteins 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6881—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/172—Haplotypes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Wood Science & Technology (AREA)
Chemical Kinetics & Catalysis (AREA)
Analytical Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Microbiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Cell Biology (AREA)
Rheumatology (AREA)
Pathology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Mycology (AREA)
Epidemiology (AREA)

AT91910085T 1990-03-30 1991-03-29 Verwendung eines mbp peptides zur herstellung eines medikamentes für die behandlung von multipler sclerose ATE210721T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US50255990A	1990-03-30	1990-03-30
PCT/US1991/002218 WO1991015225A1 (en)	1990-03-30	1991-03-29	Multiple sclerosis t-cell receptor

Publications (1)

Publication Number	Publication Date
ATE210721T1 true ATE210721T1 (de)	2001-12-15

Family

ID=23998362

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT91910085T ATE210721T1 (de)	1990-03-30	1991-03-29	Verwendung eines mbp peptides zur herstellung eines medikamentes für die behandlung von multipler sclerose

Country Status (13)

Country	Link
EP (1)	EP0522091B9 (de)
JP (1)	JPH05507911A (de)
AT (1)	ATE210721T1 (de)
AU (1)	AU651350B2 (de)
BR (1)	BR9106303A (de)
CA (1)	CA2078549C (de)
DE (1)	DE69132863T2 (de)
DK (1)	DK0522091T5 (de)
ES (1)	ES2169021T3 (de)
HU (1)	HU217847B (de)
IL (3)	IL97709A (de)
NO (1)	NO308611B1 (de)
WO (1)	WO1991015225A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6221352B1 (en)	1989-03-21	2001-04-24	The Immune Response Corporation	Method of preventing the proliferation of Vβ14 or Vβ17-Expressing T cells
US6207645B1 (en)	1989-03-21	2001-03-27	The Immune Response Corporation	Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations
CA2081672A1 (en) *	1990-05-01	1991-11-02	Lawrence Steinman	T-cell receptor variable transcripts as disease related markers
IL99699A (en)	1990-10-10	2002-04-21	Autoimmune Inc	Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH06507384A (ja) *	1991-01-22	1994-08-25	ザ　イミューン　レスポンス　コーポレイション	特定のｔ細胞群による病理的応答により生じる疾患に対するワクチン投与および方法
US6252040B1 (en)	1991-10-22	2001-06-26	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5817629A (en)	1991-10-22	1998-10-06	The Governors Of The University Of Alberta	Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
CA2126686A1 (en) *	1991-12-24	1993-07-08	Mark D. Howell	Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
US5891435A (en) *	1993-04-16	1999-04-06	Research Corporation Technologies, Inc.	Methods and compositions for delaying or preventing the onset of autoimmune disease
AU2950195A (en) *	1994-07-01	1996-01-25	Connective Therapeutics Inc.	Methods for diagnosing an immune-related disease and choosing an immune-related therapy
CA2203629A1 (en) *	1994-10-25	1996-05-02	Dawn Smilek	Compositions and treatment for multiple sclerosis
IL114458A0 (en) *	1995-07-05	1995-11-27	Yeda Res & Dev	Therapeutic preparations for treatment of T cell mediated diseases
US6488933B2 (en)	1995-07-05	2002-12-03	Yeda Research And Development Co. Ltd.	Preparations for the treatment of T cell mediated diseases
US20020009448A1 (en) *	1997-09-19	2002-01-24	Leslie P. Weiner	T-cell vaccination for the treatment of multiple sclerosis
AU6481301A (en)	2000-05-24	2001-12-03	Us Health	Methods for preventing strokes by inducing tolerance to e-selectin
HU229489B1 (hu) *	2000-08-21	2014-01-28	Apitope Technology Bristol Ltd	Tolerogén peptidek
US7658926B2 (en)	2001-09-14	2010-02-09	Opexa Pharmaceuticals, Inc.	Autologous T-cell vaccines materials and methods
PL213315B1 (pl) *	2002-06-05	2013-02-28	Baylor College Medicine	Szczepionka i zastosowanie peptydu do wytwarzania szczepionki
US7744893B2 (en)	2002-06-05	2010-06-29	Baylor College Of Medicine	T cell receptor CDR3 sequences associated with multiple sclerosis and compositions comprising same
EP2363710B1 (de)	2002-08-08	2015-07-01	Baylor College Of Medicine	Isolierung und identifizierung von t-zellen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2072356A1 (en) *	1989-12-29	1991-06-30	James L. Urban	Diagnosis and treatment of diseases

1991
- 1991-03-28 IL IL9770991A patent/IL97709A/xx not_active IP Right Cessation
- 1991-03-28 IL IL165071A patent/IL165071A/en not_active IP Right Cessation
- 1991-03-29 DK DK91910085T patent/DK0522091T5/da active
- 1991-03-29 EP EP91910085A patent/EP0522091B9/de not_active Expired - Lifetime
- 1991-03-29 HU HU9203100A patent/HU217847B/hu unknown
- 1991-03-29 BR BR919106303A patent/BR9106303A/pt not_active Application Discontinuation
- 1991-03-29 AU AU78989/91A patent/AU651350B2/en not_active Expired
- 1991-03-29 CA CA002078549A patent/CA2078549C/en not_active Expired - Lifetime
- 1991-03-29 DE DE69132863T patent/DE69132863T2/de not_active Expired - Lifetime
- 1991-03-29 AT AT91910085T patent/ATE210721T1/de not_active IP Right Cessation
- 1991-03-29 ES ES91910085T patent/ES2169021T3/es not_active Expired - Lifetime
- 1991-03-29 JP JP91509347A patent/JPH05507911A/ja active Pending
- 1991-03-29 WO PCT/US1991/002218 patent/WO1991015225A1/en not_active Ceased
1992
- 1992-09-29 NO NO923778A patent/NO308611B1/no not_active IP Right Cessation
2004
- 2004-11-07 IL IL16507104A patent/IL165071A0/xx active IP Right Grant

Also Published As

Publication number	Publication date
IL97709A0 (en)	1992-06-21
HU9203100D0 (en)	1992-12-28
DK0522091T5 (da)	2008-06-23
CA2078549A1 (en)	1991-10-01
HUT63334A (en)	1993-08-30
IL97709A (en)	2005-05-17
HU217847B (hu)	2000-04-28
NO923778L (no)	1992-11-16
NO308611B1 (no)	2000-10-02
JPH05507911A (ja)	1993-11-11
NO923778D0 (no)	1992-09-29
AU651350B2 (en)	1994-07-21
WO1991015225A1 (en)	1991-10-17
BR9106303A (pt)	1993-04-13
DK0522091T3 (da)	2002-04-08
EP0522091B1 (de)	2001-12-12
EP0522091A4 (en)	1993-05-26
IL165071A (en)	2008-06-05
AU7898991A (en)	1991-10-30
ES2169021T3 (es)	2002-07-01
IL165071A0 (en)	2005-12-18
DE69132863D1 (de)	2002-01-24
EP0522091A1 (de)	1993-01-13
EP0522091B9 (de)	2007-11-21
CA2078549C (en)	2006-07-11
DE69132863T2 (de)	2002-06-20

Legal Events

Date

Code

Title

Description

2003-03-15

UEP

Publication of translation of european patent specification

Ref document number: 0522091

Country of ref document: EP

2011-06-15

EELA

Cancelled due to lapse of time

Publication	Publication Date	Title
ATE210721T1 (de)	2001-12-15	Verwendung eines mbp peptides zur herstellung eines medikamentes für die behandlung von multipler sclerose
GB2255093A (en)	1992-10-28	Hiv-1 core protein fragments
ES2181676T3 (es)	2003-03-01	Diagnosis y tratamiento de enfermedades autoinmunitarias.
EP0674661A4 (de)	1997-12-10	Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis.
HUT70263A (en)	1995-09-28	Recombitope peptides
PT1025849E (pt)	2002-09-30	Metodos para deteccao e tratamento de individuos tendo celulas anormais que expressam antigenios do peptideo hla-a2/tirosinase
NO920331D0 (no)	1992-01-24	Biologisk preparat samt bruk derav
DK0764273T3 (da)	1999-06-23	Alfa B crystallin til anvendelse i diagnose og terapi af autoimmune sygdomme, især multipel sklerose
ES2059418T3 (es)	1994-11-16	Antigeno asociado a carcinoma humano y anticuerpo asociado al antigeno.
ATE220922T1 (de)	2002-08-15	Konjugat aus einem wirkstoff, einem polyether und ggf. einem nicht als körperfremd angesehenen, nativen protein
DE69230106D1 (de)	1999-11-11	Peptid-antigene bestehend aus multi-determinanten, die die t-helfer lymphozyten-antwort gegen hiv in einem weiten bereich von betroffenen menschen stimulieren
DE68918127D1 (de)	1994-10-20	Peptidbehandlung von hartnäckigen Infektionskrankheiten.
RU94026125A (ru)	1996-06-20	Способ диагностики синдрома вертебро-базилярной недостаточности у больных с остеохондрозом позвоночника
AU653332B2 (en)	1994-09-29	Synthetic peptides which contain sequences from factor VIIa, and the use thereof
RU94026025A (ru)	1996-05-20	Способ диагностики красного волосяного лишая девержи
FI963331A7 (fi)	1996-08-27	Dermatophagoidesista (huonepölypunkeista) peräisin olevien pääasiallisten allergeenien T-soluepitoopit
CA2151945A1 (en)	1994-07-07	Assay and treatment for demyelinating diseases such as multiple sclerosis
MX9800191A (es)	1998-05-31	Peptidos novedosos derivados de proteina humana 60 producida por choque termico, para tratamiento de diabetes, composiciones, metodos y equipos.